SK288109B6 - Extended release formulations of erythromycin derivatives - Google Patents

Extended release formulations of erythromycin derivatives Download PDF

Info

Publication number: SK288109B6
Authority: SK; Slovakia
Prior art keywords: clarithromycin; sieve; formulation; tablet; dose
Prior art date: 1997-04-11

Application number

SK1380-99A

Other languages

English (en)

Slovak (sk)

Other versions

SK138099A3 (en

Inventor

Laman A. Al-Razzak

Sheri L. Crampton

Linda E. Gustavson

Ho-Wah Hui

Nelly Milman

Susan J. Semla

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-11

Filing date

1998-03-06

Publication date

2013-08-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25278344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK288109(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-03-06 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

2000-04-10 Publication of SK138099A3 publication Critical patent/SK138099A3/sk

2013-08-02 Publication of SK288109B6 publication Critical patent/SK288109B6/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 86
238000009472 formulation Methods 0.000 title claims abstract description 60
238000013265 extended release Methods 0.000 title abstract description 3
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title description 19
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims abstract description 51
229920000642 polymer Polymers 0.000 claims abstract description 22
230000036470 plasma concentration Effects 0.000 claims abstract description 15
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 14
239000002245 particle Substances 0.000 claims abstract description 11
235000019359 magnesium stearate Nutrition 0.000 claims abstract description 7
239000000454 talc Substances 0.000 claims abstract description 7
229910052623 talc Inorganic materials 0.000 claims abstract description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
239000007916 tablet composition Substances 0.000 claims abstract description 5
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims abstract description 4
229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 claims abstract description 3
229960001021 lactose monohydrate Drugs 0.000 claims abstract description 3
229920003169 water-soluble polymer Polymers 0.000 claims abstract description 3
229960002626 clarithromycin Drugs 0.000 claims description 40
235000012222 talc Nutrition 0.000 claims description 6
-1 hydroxypropoxyl Chemical group 0.000 claims description 3
210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
230000002035 prolonged effect Effects 0.000 claims description 2
238000005550 wet granulation Methods 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
238000000034 method Methods 0.000 abstract description 13
239000003814 drug Substances 0.000 abstract description 8
230000002496 gastric effect Effects 0.000 abstract description 6
238000002360 preparation method Methods 0.000 abstract description 3
238000011282 treatment Methods 0.000 abstract description 3
208000035143 Bacterial infection Diseases 0.000 abstract description 2
241000124008 Mammalia Species 0.000 abstract description 2
208000022362 bacterial infectious disease Diseases 0.000 abstract description 2
239000003826 tablet Substances 0.000 description 44
239000012729 immediate-release (IR) formulation Substances 0.000 description 31
230000000694 effects Effects 0.000 description 15
230000002411 adverse Effects 0.000 description 13
238000013270 controlled release Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
238000013268 sustained release Methods 0.000 description 8
239000012730 sustained-release form Substances 0.000 description 8
229940087430 biaxin Drugs 0.000 description 7
235000019640 taste Nutrition 0.000 description 7
238000000576 coating method Methods 0.000 description 6
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
235000010443 alginic acid Nutrition 0.000 description 5
229920000615 alginic acid Polymers 0.000 description 5
238000000540 analysis of variance Methods 0.000 description 5
239000011248 coating agent Substances 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
210000002249 digestive system Anatomy 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000008187 granular material Substances 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
239000001863 hydroxypropyl cellulose Substances 0.000 description 5
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
210000000653 nervous system Anatomy 0.000 description 5
206010013911 Dysgeusia Diseases 0.000 description 4
239000000945 filler Substances 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
210000002345 respiratory system Anatomy 0.000 description 4
239000000523 sample Substances 0.000 description 4
229920003091 Methocel™ Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
229940072056 alginate Drugs 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
210000000748 cardiovascular system Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000001521 two-tailed test Methods 0.000 description 3
239000004606 Fillers/Extenders Substances 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000025371 Taste disease Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
239000003086 colorant Substances 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229960003276 erythromycin Drugs 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
239000012728 immediate-release (IR) tablet Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
235000019656 metallic taste Nutrition 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000006187 pill Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000009747 swallowing Effects 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000032538 Depersonalisation Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000031361 Hiccup Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000004044 Hypesthesia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920003093 Methocel™ K100 LV Polymers 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010033372 Pain and discomfort Diseases 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940045164 clarithromycin 1000 mg Drugs 0.000 description 1
229940084436 clarithromycin 500 mg Drugs 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
238000000835 electrochemical detection Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000034783 hypoesthesia Diseases 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000010985 leather Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000008693 nausea Effects 0.000 description 1
235000020925 non fasting Nutrition 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
206010037844 rash Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
230000005808 skin problem Effects 0.000 description 1
230000037321 sleepiness Effects 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
230000007480 spreading Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)

SK1380-99A 1997-04-11 1998-03-06 Extended release formulations of erythromycin derivatives SK288109B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/838,900 US6010718A (en)	1997-04-11	1997-04-11	Extended release formulations of erythromycin derivatives
PCT/US1998/004373 WO1998046239A1 (en)	1997-04-11	1998-03-06	Extended release formulations of erythromycin derivatives

Publications (2)

Publication Number	Publication Date
SK138099A3 SK138099A3 (en)	2000-04-10
SK288109B6 true SK288109B6 (sk)	2013-08-02

Family

ID=25278344

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SK1380-99A SK288109B6 (sk)	1997-04-11	1998-03-06	Extended release formulations of erythromycin derivatives
SK5021-2010A SK288127B6 (sk)	1997-04-11	1998-03-06	Pharmaceutical formulation with extended release of clarithromycin and use thereof

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SK5021-2010A SK288127B6 (sk)	1997-04-11	1998-03-06	Pharmaceutical formulation with extended release of clarithromycin and use thereof

Country Status (28)

Country	Link
US (1)	US6010718A (pl)
EP (2)	EP1340495B1 (pl)
JP (2)	JP4394754B2 (pl)
KR (1)	KR100484559B1 (pl)
CN (1)	CN100408044C (pl)
AR (1)	AR012358A1 (pl)
AT (1)	ATE253371T1 (pl)
AU (1)	AU737324B2 (pl)
BG (1)	BG65188B1 (pl)
BR (1)	BR9807974A (pl)
CA (1)	CA2285266C (pl)
CO (1)	CO4940403A1 (pl)
CZ (1)	CZ294333B6 (pl)
DE (1)	DE69819481T2 (pl)
DK (1)	DK0973527T3 (pl)
ES (1)	ES2205454T3 (pl)
HU (1)	HUP0001382A3 (pl)
IL (3)	IL131616A0 (pl)
NO (1)	NO994946D0 (pl)
NZ (3)	NZ537410A (pl)
PL (2)	PL336142A1 (pl)
PT (1)	PT973527E (pl)
SA (1)	SA98190065B1 (pl)
SK (2)	SK288109B6 (pl)
TR (2)	TR199902149T2 (pl)
TW (1)	TW576743B (pl)
WO (1)	WO1998046239A1 (pl)
ZA (1)	ZA982916B (pl)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6551616B1 (en)	1997-04-11	2003-04-22	Abbott Laboratories	Extended release formulations of erythromycin derivatives
AU773863B2 (en) *	1997-04-11	2004-06-10	Bgp Products Operations Gmbh	Extended release formulations of erythromycin derivatives
US6099859A (en) *	1998-03-20	2000-08-08	Andrx Pharmaceuticals, Inc.	Controlled release oral tablet having a unitary core
TR200000054A2 (tr) *	2000-01-05	2001-08-21	Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇	Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
US6544555B2 (en) *	2000-02-24	2003-04-08	Advancis Pharmaceutical Corp.	Antibiotic product, use and formulation thereof
US6565882B2 (en) *	2000-02-24	2003-05-20	Advancis Pharmaceutical Corp	Antibiotic composition with inhibitor
WO2001064224A1 (en) *	2000-02-29	2001-09-07	Teva Pharmaceutical Industries Ltd.	Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
ATE432691T1 (de) *	2000-03-28	2009-06-15	Sandoz Ag	Geschmackmaskierte granulierte teilchen
IN192748B (pl) *	2000-08-29	2004-05-15	Ranbaxy Lab Ltd
CA2425688A1 (en) *	2000-10-13	2002-05-16	Donald J. Treacy Jr.	Extended release erythromycin derivatives
US20020068078A1 (en) *	2000-10-13	2002-06-06	Rudnic Edward M.	Antifungal product, use and formulation thereof
US6541014B2 (en) *	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
US6790459B1 (en)	2000-11-03	2004-09-14	Andrx Labs, Llc	Methods for treating diabetes via administration of controlled release metformin
US6866866B1 (en)	2000-11-03	2005-03-15	Andrx Labs, Llc	Controlled release metformin compositions
US20060034922A1 (en) *	2000-11-03	2006-02-16	Andrx Labs, Llc	Controlled release metformin compositions
US20020197314A1 (en) *	2001-02-23	2002-12-26	Rudnic Edward M.	Anti-fungal composition
US6673369B2 (en)	2001-08-29	2004-01-06	Ranbaxy Laboratories Limited	Controlled release formulation
BR0212259A (pt) *	2001-08-29	2004-10-19	Ranbaxy Lab Ltd	Formulação de liberação controlada de claritromicina ou tinidazol
US20050233003A1 (en) *	2001-09-28	2005-10-20	Solubest Ltd.	Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US20050191359A1 (en) *	2001-09-28	2005-09-01	Solubest Ltd.	Water soluble nanoparticles and method for their production
US20050227911A1 (en) *	2001-09-28	2005-10-13	Solubest Ltd.	Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US6878693B2 (en) *	2001-09-28	2005-04-12	Solubest Ltd.	Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050249786A1 (en) *	2001-09-28	2005-11-10	Solubest Ltd.	Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
CA2465405A1 (en) *	2001-11-02	2003-05-08	Wockhardt Limited	Controlled release compositions for macrolide antimicrobial agents
US7700851B2 (en) *	2001-11-13	2010-04-20	U.S. Smokeless Tobacco Company	Tobacco nicotine demethylase genomic clone and uses thereof
PL223471B1 (pl) *	2002-03-15	2016-10-31	Cypress Bioscience Inc	Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego
US20040052848A1 (en) *	2002-05-23	2004-03-18	Xiu-Xiu Cheng	Biguanide formulations
AU2003245504A1 (en) *	2002-06-14	2003-12-31	Andrx Corporation	Pharmaceutical compositions for drugs having ph-dependentsolubility
US20060003004A1 (en) *	2002-10-25	2006-01-05	Collegium Pharmaceutical, Inc.	Pulsatile release compositions of milnacipran
US20040121010A1 (en) *	2002-10-25	2004-06-24	Collegium Pharmaceutical, Inc.	Pulsatile release compositions of milnacipran
US20040191302A1 (en)	2003-03-28	2004-09-30	Davidson Robert S.	Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US9561182B2 (en) *	2003-08-22	2017-02-07	Cure Pharmaceutical Corporation	Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US8999372B2 (en) *	2002-11-14	2015-04-07	Cure Pharmaceutical Corporation	Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US20040131662A1 (en)	2003-11-12	2004-07-08	Davidson Robert S.	Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
WO2004067039A1 (en) *	2003-01-28	2004-08-12	Collegium Pharmaceutical, Inc.	Multiparticulate compositions of milnacipran for oral administration
US20040185097A1 (en) *	2003-01-31	2004-09-23	Glenmark Pharmaceuticals Ltd.	Controlled release modifying complex and pharmaceutical compositions thereof
BRPI0410098A (pt) *	2003-05-06	2006-05-16	Nirmal Mulye	formulação de liberação controlada de derivados de eritromicina
US7063862B2 (en) *	2003-06-03	2006-06-20	Biokey, Inc.	Pharmaceutical composition and method for treating
AU2004249211A1 (en) *	2003-06-16	2004-12-29	Andrx Pharmaceuticals, Llc	Oral extended-release composition
US20050053658A1 (en) *	2003-09-09	2005-03-10	Venkatesh Gopi M.	Extended release systems for macrolide antibiotics
CA2533178C (en) *	2003-07-21	2014-03-11	Advancis Pharmaceutical Corporation	Antibiotic product, use and formulation thereof
US8425936B2 (en) *	2003-07-21	2013-04-23	Shionogi Inc.	Antibiotic product, use and formulation thereof
US8313775B2 (en) *	2003-07-21	2012-11-20	Shionogi Inc.	Antibiotic product, use and formulation thereof
JP2007502296A (ja) *	2003-08-11	2007-02-08	アドバンシスファーマスーティカルコーポレイション	ロバストペレット
CA2535398C (en) *	2003-08-12	2013-11-12	Advancis Pharmaceuticals Corporation	Antibiotic product, use and formulation thereof
AU2004270170B2 (en) *	2003-08-29	2011-01-27	Shionogi, Inc.	Antibiotic product, use and formulation thereof
WO2005023221A1 (en) *	2003-09-05	2005-03-17	Ranbaxy Laboratories Limited	Clarithromycin formulations having improved biovailability
WO2005027877A1 (en) *	2003-09-15	2005-03-31	Advancis Pharmaceutical Corporation	Antibiotic product, use and formulation thereof
US8168228B2 (en) *	2003-10-17	2012-05-01	Sandoz Ag	Antibiotic clarithromycin micropellet compositions
US20050084540A1 (en) *	2003-10-17	2005-04-21	Indranil Nandi	Taste masking antibiotic composition
AU2004286855B2 (en)	2003-10-29	2011-04-21	Wyeth	Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
US20050101547A1 (en) *	2003-11-06	2005-05-12	Sadatrezaei Mohsen	Stabilized azithromycin composition
US6984403B2 (en) *	2003-12-04	2006-01-10	Pfizer Inc.	Azithromycin dosage forms with reduced side effects
WO2005053652A1 (en)	2003-12-04	2005-06-16	Pfizer Products Inc.	Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053639A2 (en) *	2003-12-04	2005-06-16	Pfizer Products Inc.	Controlled release multiparticulates formed with dissolution enhancers
CA2549225A1 (en) *	2003-12-04	2005-06-16	Pfizer Products Inc.	Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
CA2547597A1 (en) *	2003-12-04	2005-06-16	Pfizer Products Inc.	Multiparticulate compositions with improved stability
RU2006119464A (ru) *	2003-12-04	2007-12-20	Пфайзер Продактс Инк. (Us)	Способ распыления-охлаждения с применением экструдера для получения композиций азитромицина в мультичастицах, предпочтительно содержащих полоксамер и глицерид
AU2004294817B2 (en) *	2003-12-04	2007-01-25	Pfizer Products Inc.	Method for making pharmaceutical multiparticulates
KR20060092281A (ko) *	2003-12-04	2006-08-22	화이자 프로덕츠 인크.	액체 기초 방법에 의한 아지트로마이신 복합입자 투여형
US7943585B2 (en)	2003-12-22	2011-05-17	Sandoz, Inc.	Extended release antibiotic composition
WO2005062898A2 (en) *	2003-12-24	2005-07-14	Advancis Pharmaceutical Corporation	Enhanced absorption of modified release dosage forms
BRPI0508743A (pt) *	2004-03-24	2008-01-22	Lupin Ltd	composição farmacêutica com uma liberação estendida de eritromicina ou um derivado da mesma, método para o uso de uma composição farmacêutica e processo para a preparação de uma composição farmacêutica
US20050260263A1 (en) *	2004-05-18	2005-11-24	Panion & Bf Biotech Inc.	Sustained release formulation for sparingly soluble main drugs
KR101122096B1 (ko) *	2004-05-20	2012-03-15	주식회사종근당	쓴맛을 차폐하면서 우수한 용출률을 보이는클라리스로마이신의 약제학적 조성물 및 그의 제조 방법
KR100621342B1 (ko) *	2004-06-22	2006-09-18	(주)다산메디켐	클래리스로마이신-함유 약제학적 조성물 및 그의 제조방법
WO2006014427A1 (en) *	2004-07-02	2006-02-09	Advancis Pharmaceutical Corporation	Tablet for pulsed delivery
US8778924B2 (en) *	2006-12-04	2014-07-15	Shionogi Inc.	Modified release amoxicillin products
US8357394B2 (en)	2005-12-08	2013-01-22	Shionogi Inc.	Compositions and methods for improved efficacy of penicillin-type antibiotics
TW200800233A (en) *	2006-04-28	2008-01-01	Shionogi & Amp Co Ltd	A coated preparation of macrolide antibiotics
US8299052B2 (en)	2006-05-05	2012-10-30	Shionogi Inc.	Pharmaceutical compositions and methods for improved bacterial eradication
JP2009539866A (ja) *	2006-06-05	2009-11-19	オースペックス・ファーマシューティカルズ・インコーポレイテッド	置換エリスロマイシンアナログの調製および有用性
EP2283824B1 (en)	2009-07-30	2017-04-19	Special Products Line S.p.A.	Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
EP2671571A1 (en)	2012-06-05	2013-12-11	Sanovel Ilac Sanayi ve Ticaret A.S.	Controlled-release formulations of clarithromycin
EP3784227A4 (en) *	2018-04-25	2022-03-02	Neurocentria, Inc.	MAGNESIUM THREONATE COMPOSITIONS AND THEIR USES
ES3052394T3 (en) *	2020-07-13	2026-01-07	Kirin Holdings Kk	Film coated tablet

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3870790A (en) *	1970-01-22	1975-03-11	Forest Laboratories	Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4226849A (en) *	1979-06-14	1980-10-07	Forest Laboratories Inc.	Sustained release therapeutic compositions
US4369172A (en) *	1981-12-18	1983-01-18	Forest Laboratories Inc.	Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
ATE66143T1 (de) *	1985-01-11	1991-08-15	Abbott Lab	Feste zubereitung mit langsamer freisetzung.
FR2585948B1 (fr) *	1985-08-06	1988-12-16	Pf Medicament	Procede de fabrication de comprimes d'indometacine
US4808411A (en) *	1987-06-05	1989-02-28	Abbott Laboratories	Antibiotic-polymer compositions
US4925675A (en)	1988-08-19	1990-05-15	Himedics, Inc.	Erythromycin microencapsulated granules
JP3265680B2 (ja) *	1992-03-12	2002-03-11	大正製薬株式会社	経口製剤用組成物
US5393765A (en) *	1993-12-13	1995-02-28	Hoffmann-La Roche Inc.	Pharmaceutical compositions with constant erosion volume for zero order controlled release
ATE209497T1 (de) *	1994-05-06	2001-12-15	Pfizer	Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
JPH0995440A (ja) *	1995-09-29	1997-04-08	Roussel Morishita Kk	徐放性製剤およびその製造方法
US5919489A (en) *	1995-11-01	1999-07-06	Abbott Laboratories	Process for aqueous granulation of clarithromycin
US5705190A (en) *	1995-12-19	1998-01-06	Abbott Laboratories	Controlled release formulation for poorly soluble basic drugs
US5972389A (en) *	1996-09-19	1999-10-26	Depomed, Inc.	Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter

1997
- 1997-04-11 US US08/838,900 patent/US6010718A/en not_active Expired - Lifetime
1998
- 1998-03-06 KR KR10-1999-7009335A patent/KR100484559B1/ko not_active Expired - Fee Related
- 1998-03-06 SK SK1380-99A patent/SK288109B6/sk not_active IP Right Cessation
- 1998-03-06 AT AT98907722T patent/ATE253371T1/de active
- 1998-03-06 CZ CZ19993471A patent/CZ294333B6/cs not_active IP Right Cessation
- 1998-03-06 PL PL98336142A patent/PL336142A1/xx not_active IP Right Cessation
- 1998-03-06 DE DE69819481T patent/DE69819481T2/de not_active Revoked
- 1998-03-06 CA CA002285266A patent/CA2285266C/en not_active Expired - Lifetime
- 1998-03-06 PL PL402949A patent/PL402949A1/pl not_active Application Discontinuation
- 1998-03-06 BR BR9807974-3A patent/BR9807974A/pt not_active Application Discontinuation
- 1998-03-06 SK SK5021-2010A patent/SK288127B6/sk not_active IP Right Cessation
- 1998-03-06 NZ NZ537410A patent/NZ537410A/en not_active IP Right Cessation
- 1998-03-06 AU AU63463/98A patent/AU737324B2/en not_active Expired
- 1998-03-06 EP EP03008281.2A patent/EP1340495B1/en not_active Expired - Lifetime
- 1998-03-06 TR TR1999/02149T patent/TR199902149T2/xx unknown
- 1998-03-06 WO PCT/US1998/004373 patent/WO1998046239A1/en not_active Ceased
- 1998-03-06 ES ES98907722T patent/ES2205454T3/es not_active Expired - Lifetime
- 1998-03-06 PT PT98907722T patent/PT973527E/pt unknown
- 1998-03-06 NZ NZ337120A patent/NZ337120A/en not_active IP Right Cessation
- 1998-03-06 TR TR2007/07263T patent/TR200707263T2/xx unknown
- 1998-03-06 EP EP98907722A patent/EP0973527B1/en not_active Revoked
- 1998-03-06 JP JP54388298A patent/JP4394754B2/ja not_active Expired - Fee Related
- 1998-03-06 CN CNB03157906XA patent/CN100408044C/zh not_active Expired - Fee Related
- 1998-03-06 IL IL13161698A patent/IL131616A0/xx unknown
- 1998-03-06 DK DK98907722T patent/DK0973527T3/da active
- 1998-03-06 NZ NZ596215A patent/NZ596215A/xx not_active IP Right Cessation
- 1998-03-06 HU HU0001382A patent/HUP0001382A3/hu unknown
- 1998-03-17 TW TW087103954A patent/TW576743B/zh not_active IP Right Cessation
- 1998-04-06 ZA ZA982916A patent/ZA982916B/xx unknown
- 1998-04-07 AR ARP980101591A patent/AR012358A1/es not_active Application Discontinuation
- 1998-04-08 CO CO98019851A patent/CO4940403A1/es unknown
- 1998-05-16 SA SA98190065A patent/SA98190065B1/ar unknown
1999
- 1999-08-26 IL IL131616A patent/IL131616A/en not_active IP Right Cessation
- 1999-10-11 NO NO994946A patent/NO994946D0/no unknown
- 1999-11-05 BG BG103862A patent/BG65188B1/bg unknown
2009
- 2009-01-07 JP JP2009001631A patent/JP5188994B2/ja not_active Expired - Fee Related
2012
- 2012-11-14 IL IL223035A patent/IL223035A0/en unknown

Also Published As

Publication number	Publication date
HK1027023A1 (en)	2001-01-05
SA98190065B1 (ar)	2006-06-17
SK288127B6 (sk)	2013-10-02
CZ294333B6 (cs)	2004-12-15
PL336142A1 (en)	2000-06-05
AU737324B2 (en)	2001-08-16
JP4394754B2 (ja)	2010-01-06
PL402949A1 (pl)	2013-04-15
HUP0001382A2 (hu)	2000-09-28
CA2285266A1 (en)	1998-10-22
KR20010006251A (ko)	2001-01-26
IL131616A (en)	2013-03-24
HUP0001382A3 (en)	2001-08-28
ATE253371T1 (de)	2003-11-15
EP0973527A1 (en)	2000-01-26
TR199902149T2 (xx)	1999-12-21
CO4940403A1 (es)	2000-07-24
AU6346398A (en)	1998-11-11
JP2001524955A (ja)	2001-12-04
DK0973527T3 (da)	2003-11-24
BG65188B1 (bg)	2007-06-29
BR9807974A (pt)	2000-03-08
NZ596215A (en)	2013-09-27
IL223035A0 (en)	2012-12-31
EP1340495B1 (en)	2016-08-10
CZ347199A3 (cs)	2000-01-12
WO1998046239A1 (en)	1998-10-22
AR012358A1 (es)	2000-10-18
KR100484559B1 (ko)	2005-04-22
EP1340495A1 (en)	2003-09-03
EP0973527B1 (en)	2003-11-05
IL131616A0 (en)	2001-01-28
TR200707263T2 (tr)	2008-01-21
TW576743B (en)	2004-02-21
JP5188994B2 (ja)	2013-04-24
NZ337120A (en)	2001-04-27
JP2009137988A (ja)	2009-06-25
SK138099A3 (en)	2000-04-10
PT973527E (pt)	2004-01-30
NO994946L (no)	1999-10-11
US6010718A (en)	2000-01-04
CA2285266C (en)	2001-07-24
CN1494911A (zh)	2004-05-12
NO994946D0 (no)	1999-10-11
NZ537410A (en)	2007-06-29
BG103862A (en)	2000-07-31
DE69819481T2 (de)	2004-08-26
DE69819481D1 (de)	2003-12-11
ES2205454T3 (es)	2004-05-01
CN100408044C (zh)	2008-08-06
ZA982916B (en)	1998-10-09

Publication	Publication Date	Title
SK288109B6 (sk)	2013-08-02	Extended release formulations of erythromycin derivatives
US6551616B1 (en)	2003-04-22	Extended release formulations of erythromycin derivatives
US20050064033A1 (en)	2005-03-24	Extended release formulations of erythromycin derivatives
CA2358395C (en)	2004-07-27	Extended release formulations of erythromycin derivatives
AU773863B2 (en)	2004-06-10	Extended release formulations of erythromycin derivatives
AU2003270948B2 (en)	2007-03-15	Extended Release Formulations of Erythromycin Derivatives
AU2007201031B2 (en)	2009-07-23	Extended release formulations of erythromycin derivatives
CA2325541C (en)	2001-10-09	Extended release formulations of erythromycin derivatives
RU2603469C2 (ru)	2016-11-27	Таблетка с контролируемым высвобождением для перорального введения и способ ее приготовления
HK1027023B (en)	2004-10-15	Extended release formulations of clarithromycin
CA2465698A1 (en)	1998-10-22	Extended release formulations of erythromycin derivatives
AU2006201001A1 (en)	2006-03-30	Extended release formulations of erythromycin derivatives

Legal Events

Date	Code	Title	Description
2016-06-01	PC4A	Assignment and transfer of rights	Owner name: BGP PRODUCTS OPERATIONS GMBH, ALLSCHWIL, CH Free format text: FORMER OWNER: ABBOTT LABORATORIES, ABBOTT PARK, IL, US Effective date: 20160523
2018-05-02	MK4A	Patent expired	Expiry date: 20180306

Date

Code

Title

Description

2016-06-01

PC4A

Assignment and transfer of rights

Owner name: BGP PRODUCTS OPERATIONS GMBH, ALLSCHWIL, CH

Free format text: FORMER OWNER: ABBOTT LABORATORIES, ABBOTT PARK, IL, US

Effective date: 20160523

2018-05-02

MK4A

Patent expired

Expiry date: 20180306